Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G.

Nucleic Acids Res. 2009 Jun;37(11):3660-9. doi: 10.1093/nar/gkp226. Epub 2009 Apr 15.

2.

Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.

Jern P, Russell RA, Pathak VK, Coffin JM.

PLoS Pathog. 2009 Apr;5(4):e1000367. doi: 10.1371/journal.ppat.1000367. Epub 2009 Apr 3.

3.

Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.

Browne EP, Allers C, Landau NR.

Virology. 2009 May 10;387(2):313-21. doi: 10.1016/j.virol.2009.02.026. Epub 2009 Mar 21.

5.

APOBEC3G inhibits elongation of HIV-1 reverse transcripts.

Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH.

PLoS Pathog. 2008 Dec;4(12):e1000231. doi: 10.1371/journal.ppat.1000231. Epub 2008 Dec 5.

6.

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51. Review.

7.

Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.

Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA.

J Virol. 2008 Aug;82(16):8172-82. doi: 10.1128/JVI.01115-08. Epub 2008 Jun 11.

8.

HIV-1 accessory proteins--ensuring viral survival in a hostile environment.

Malim MH, Emerman M.

Cell Host Microbe. 2008 Jun 12;3(6):388-98. doi: 10.1016/j.chom.2008.04.008. Review.

9.

Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

Haché G, Shindo K, Albin JS, Harris RS.

Curr Biol. 2008 Jun 3;18(11):819-24. doi: 10.1016/j.cub.2008.04.073. Epub 2008 May 22.

10.

Cytidine deamination induced HIV-1 drug resistance.

Mulder LC, Harari A, Simon V.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5501-6. doi: 10.1073/pnas.0710190105. Epub 2008 Apr 7.

11.

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.

Chiu YL, Greene WC.

Annu Rev Immunol. 2008;26:317-53. doi: 10.1146/annurev.immunol.26.021607.090350. Review.

PMID:
18304004
12.

The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.

Schumacher AJ, Haché G, Macduff DA, Brown WL, Harris RS.

J Virol. 2008 Mar;82(6):2652-60. doi: 10.1128/JVI.02391-07. Epub 2008 Jan 9.

13.
14.

Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K.

J Virol. 2007 Dec;81(24):13346-53. Epub 2007 Oct 10.

15.

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

Li XY, Guo F, Zhang L, Kleiman L, Cen S.

J Biol Chem. 2007 Nov 2;282(44):32065-74. Epub 2007 Sep 12.

16.

The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L.

J Virol. 2007 Oct;81(20):11322-31. Epub 2007 Aug 1.

17.

Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.

Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK.

J Virol. 2007 Jul;81(13):7099-110. Epub 2007 Apr 11.

18.

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu XF.

J Virol. 2007 Jul;81(13):7238-48. Epub 2007 Apr 11.

19.

Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.

Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK.

Virology. 2007 Apr 10;360(2):247-56. Epub 2006 Nov 28.

20.

APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.

Holmes RK, Koning FA, Bishop KN, Malim MH.

J Biol Chem. 2007 Jan 26;282(4):2587-95. Epub 2006 Nov 22.

Supplemental Content

Support Center